<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206907</url>
  </required_header>
  <id_info>
    <org_study_id>EN3319-301</org_study_id>
    <nct_id>NCT01206907</nct_id>
  </id_info>
  <brief_title>Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects</brief_title>
  <official_title>AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER EFFECTIVENESS, SAFETY AND TOLERABILITY STUDY OF OXYMORPHONE HCl IMMEDIATE-RELEASE ORAL LIQUID IN OPIOID-TOLERANT PEDIATRIC SUBJECTS WITH CHRONIC PAIN REQUIRING AN AROUND THE CLOCK OPIOID</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness, tolerability, and safety of
      oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having
      severe to moderate chronic pain.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study is no longer required for the PREA for this product.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain intensity from baseline to last assessment using the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale.</measure>
    <time_frame>weekly for 1 month during titration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pain intensity from baseline to last assessment using the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale.</measure>
    <time_frame>bi-weekly for three months in the maintenance phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment of Adverse Events, vital signs including oxygen saturation, Blood Pressure, and Heart Rate.</measure>
    <time_frame>weekly for 1 month during titration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment of Adverse Events, vital signs including oxygen saturation, Blood Pressure, and Heart Rate.</measure>
    <time_frame>bi-weekly for 3 months in the maintenance phase</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxymorphone IR</intervention_name>
    <description>oxymorphone IR liquid</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females 2 to ≤6 years of age, inclusive

          2. Chronic cancer or non-cancer pain, currently requiring treatment of pain with a strong
             opioid for at least 5 days (3 of 5 days at a dose &gt;1 mg/kg qd oral morphine
             equivalent)

          3. Expected to continue to require a strong opioid for pain relief for at least 4 months

          4. Able to swallow the oxymorphone HCl immediate-release oral liquid

          5. Have been informed of the nature of the study and informed consent and assent by minor
             (if IRB required) has been obtained from the legally responsible parent/legal guardian
             in accordance with IRB requirements

        Exclusion Criteria:

          1. Known allergy to, or a significant reaction to, oxymorphone or another opioid

          2. Life expectancy &lt;4 months

          3. Any clinical condition in the investigator's opinion that would preclude participation

          4. Plan to undergo a surgical procedure within 1 month of study entry or anytime during
             study

          5. Currently prescribed a long-acting opioid (eg., Kadian® morphine sulfate extended
             release) as part of their analgesic regimen

          6. Received any investigational medication within 30 days prior to the first dose of
             study medication, or are scheduled to receive an investigational drug other than
             oxymorphone during the course of the study

          7. An ileostomy

          8. Received a monoamine oxidase inhibitor (MAOI) within 14 days prior to the start of
             study medication

          9. Investigator anticipates that the subject would be unable to comply with the protocol

         10. Parent/legal guardian is unable to complete the subject's daily study medication diary

         11. Parent/legal guardian is unable to effectively communicate the subject's status to the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2010</study_first_posted>
  <last_update_submitted>August 15, 2012</last_update_submitted>
  <last_update_submitted_qc>August 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <name_title>Sr. Director CR &amp; D</name_title>
    <organization>Endo Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>sickle cell anemia</keyword>
  <keyword>juvenile rheumatoid arthritis</keyword>
  <keyword>burn victim</keyword>
  <keyword>cancer</keyword>
  <keyword>Chronic pain of malignant or non-malignant etiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

